Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors

NCT00929903 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00929903
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00929903 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2009
Completion date
Not reported
Enrollment
55 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

childhood central nervous system choriocarcinoma, childhood central nervous system embryonal tumor, childhood central nervous system germ cell tumor, childhood central nervous system germinoma, childhood central nervous system mixed germ cell tumor, childhood central nervous system teratoma, childhood central nervous system yolk sac tumor, metastatic childhood soft tissue sarcoma, recurrent childhood brain stem glioma, recurrent childhood central nervous system embryonal tumor, recurrent childhood soft tissue sarcoma, recurrent childhood visual pathway glioma, unspecified childhood solid tumor, protocol specific